tbuckley/cabot-search huggingface dataset:
Risk of Motor Vehicle Crashes in Patients With Cataract Surgery
Authors: Jonathan C Javitt
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
4-(4-bromopheny1)-2,3-dihydro-N,3-bis(3,4,5-trimethoxyphenyl)-2-oxoidmidazole-1-carboxamide induces apoptosis in human leukemia cells through mitochondrial pathway
Authors: Liang Fang, Qiaojun He, Bo Yang
Journal: Cancer Research (2006)

4709   4-(4-bromopheny1)-2,3-dihydro-N,3-bis(3,4,5-trimethoxyphenyl)-2-oxoidmidazole-1-carboxamide (MZ3), one of 2-oxo-N,3,4-trisubstituted-penylimidazoline-1-carboxamides modified from Combretastatin A-4 (a potent agent of  Combretum Caffrum ), displayed a specific activity against leukemia cell lines. A panel of six human leukemia cells (HL60, K562, Molt-4 and NB4, 2 multi-drug resistant cell lines: HL60R, K562R) were employed to determine the cytotoxicity through MTT assay and flow cytometry. MZ3 exhibited high anti-leukemia activity in all cell lines with IC 50  values ranged from 1.2 μM to 8.0 μM. MZ3 (4.0 μM for 6 - 72 h) induced apoptosis in 2.5 % - 85.4 % of HL60 cells in a time-dependent manner. By fluorescence stain assay, an elevation of reactive oxygen species (ROS) level was observed in HL60 cells treated with 8.0 μM MZ3 at 2 hours, preceding an occurrence of mitochondrial membrane potential (ΔΨ m ) loss at 8 h, indicating that MZ3 activated the mitochondrial pathway of apoptosis via ROS. The loss of ΔΨ m  was reported as a pro-apoptotic factor that could induce the activation of caspase cascade, therefore we tested the expression of proteins related to apoptosis by western blot. The results showed that MZ3 induced the activation of procaspase-3 and subsequent cleavage of its substrate poly (ADP-ribose) polymerase (PARP), while decreased the expression of the x-linked inhibitor of apoptosis protein (XIAP), an anti-apoptotic protein. Since it was reported that the stabilization of mitochondrial membrane is regulated by the Bcl-2 family proteins and the ratio of Bax to Bcl-2 within a cell is critical for the cellular response to apoptotic stimuli, we determined protein expression of Bax and Bcl-2, and found a >4-fold increase of Bax/Bcl-2 ratio in HL60 cells treated with 8.0 μM MZ3 for 24 h. To supplement our results, the activity assay  in vivo  was performed on severe combined immunodeficiency (SCID) mice model of human leukemia engraftment. The median survival time (MST) in treatment group, administrated (i.m.) with 10 mg/kg MZ3 daily for 10 consecutive days, was significantly prolonged ( P   in vitro  and  in vivo , and mitochondrial pathway might be involved in the activation of a caspase cascade to induce cell apoptosis.
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Authors: Neeta Pandit-Taskar, Joseph A. O'Donoghue, Jeremy C. Durack, Serge K. Lyashchenko, Sarah M. Cheal, Volkan Beylergil, Robert A. Lefkowitz, Jorge A. Carrasquillo, Danny F. Martinez, Alex Mak Fung, Stephen B. Solomon, Mithat Gönen, Glenn Heller, Massimo Loda, David M. Nanus, Scott T. Tagawa, Jarett L. Feldman, Joseph R. Osborne, Jason S. Lewis, Victor E. Reuter, Wolfgang A. Weber, Neil H. Bander, Howard I. Scher, Steven M. Larson, Michael J. Morris
Journal: Clinical Cancer Research (2015)

Standard imaging for assessing osseous metastases in advanced prostate cancer remains focused on altered bone metabolism and is inadequate for diagnostic, prognostic, or predictive purposes. We performed a first-in-human phase I/II study of (89)Zr-DFO-huJ591 ((89)Zr-J591) PET/CT immunoscintigraphy to assess performance characteristics for detecting metastases compared with conventional imaging modalities (CIM) and pathology.Fifty patients with progressive metastatic castration-resistant prostate cancers were injected with 5 mCi of (89)Zr-J591. Whole-body PET/CT scans were obtained, and images were analyzed for tumor visualization. Comparison was made to contemporaneously obtained bone scintigraphy and cross-sectional imaging on a lesion-by-lesion basis and with biopsies of metastatic sites.Median standardized uptake value for (89)Zr-J591-positive bone lesions (n = 491) was 8.9 and for soft-tissue lesions (n = 90), it was 4.8 (P < 0.00003). (89)Zr-J591 detected 491 osseous sites compared with 339 by MDP and 90 soft-tissue lesions compared with 124 by computed tomography (CT). Compared with all CIMs combined, (89)Zr-J591 detected an additional 99 osseous sites. Forty-six lesions (21 bone and 25 soft tissue) were biopsied in 34 patients; 18 of 19 (89)Zr-J591-positive osseous sites and 14 of 16 (89)Zr-J591-positive soft tissue sites were positive for prostate cancer. The overall accuracy of (89)Zr-J591 was 95.2% (20 of 21) for osseous lesions and 60% (15 of 25) for soft-tissue lesions.(89)Zr-J591 imaging demonstrated superior targeting of bone lesions relative to CIMs. Targeting soft-tissue lesions was less optimal, although (89)Zr-J591 had similar accuracy as individual CIMs. This study will provide benchmark data for comparing performance of proposed prostate-specific membrane antigen (PSMA) targeting agents for prostate cancer.
Abstract 20118: Wnt1 Mediated Dynamic Injury Response Activates the Epicardium and is Critical for Mammalian Cardiac Repair
Authors: Arjun Deb, Costin Gherghe, Dianxin Liu, Eric Hamlett, Luxman Srikanth, Biplab Giri, Laurel Rodgers, Jenna Regan, Jackie Kylander, Mauricio Rojas, Andrew Leask, Mark Majesky, Jinzhu Duan
Journal: Circulation (2010)

The epicardium is activated following acute cardiac injury in zebrafish and plays a critical role in heart regeneration. The role of the mammalian epicardium in cardiac repair is unknown. The Wnt s...
Abstract 19813: Sleep Disturbance, Heart Failure, and Cognitive Function in Older Individuals: The Aging Demographics, and Memory Study (ADAMS)
Authors: Chooza Moon, Ju Young Yoon, Diane R Lauver, Lisa Bratzke
Journal: Circulation (2014)

Introduction: Approximately 50% of heart failure (HF) patients experience cognitive decline. In the general population, sleep disturbance is associated with cognitive decline. Sleep disturbance may alter the cellular or chemical homeostasis triggering cognitive decline. Up to 70% of individuals with HF report sleep disturbance. Although the etiology of cognitive decline in HF is unknown, sleep fragmentation and short sleep duration from sleep disturbance may partially explain cognitive decline among individuals with HF. This study investigates the possible mediating role of sleep disturbance on the relationship between HF and cognition. Methods: This cross-sectional study examined 856 older adults’ (mean age: 81.6 years, SD: 7.1, male: 355 (41%), Caucasian: 658 (77 %), HF: 100 (11.7%)) data from Aging, Demographics, and Memory Study. To explore the possibility of meditating effects of sleep disturbance on relationship between HF and cognition, we used a structural equation model. Cognition was measured by neuropyshological tests. Sleep disturbance was determined if a subject was positive on one of the following three questions: 1) “Do you have problem falling asleep?”, 2) “Do you wake frequently during sleep?”, and 3) “Do you wake up too early?” Results: Individuals with HF were likely to have a higher degree of sleep disturbance (β=0.229,p=0.003). Sleep disturbance was a significant predictor of cognitive decline (β=-6.52,p=0.028). However, there was no significant mediating effect of sleep disturbance on the relationship between HF and cognition (β=-0.011,p=0.978) after controlling for age, sex, and comorbidities. Conclusion: Findings from this study suggest that HF can exacerbate sleep disturbance and sleep disturbance can deteriorate cognition. However, the mediating role of sleep disturbance on the relationship between HF and cognitive decline remains questionable. Future studies using objective measures and longitudinal design would enhance our knowledge related to the relationship between heart failure, sleep disturbance, and cognition.
Linezolid and Reversible Myelosuppression—Reply
Authors: Stephen L. Green
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prospective audit of incidence of prognostically important myocardial damage in patients discharged from emergency department Commentary: Time for improved diagnosis and management of patients presenting with acute chest pain
Authors: P O Collinson
Journal: BMJ (2000)

To assess the incidence of prognostically important myocardial damage in patients with chest pain discharged from the emergency department.Prospective observational study.District general hospital emergency department.110 patients presenting with chest pain of unknown cause who were subsequently discharged home after cardiac causes of chest pain were ruled out by clinical and electrocardiographic investigation.Patients were reviewed 12-48 hours after presentation by repeat electrocardiography and measurement of cardiac troponin T.Incidence of missed myocardial damage.Eight (7%) patients had detectable cardiac troponin T on review and seven had concentrations >/=0.1 microg/l. The repeat electrocardiogram showed no abnormality in any patient.6% of the patients discharged from the emergency department had missed prognostically important myocardial damage. Follow up measurement of cardiac troponin T allows convenient audit of clinical performance in the emergency department.
Possible Role of Histamine in Rheumatoid Arthritis.
Authors: H. Permin, P. Stahl Skov, S. Norn, A. Geisler, R. Klysner, V. Andersen, A. Wiik, R. Manthorpe, H. Nielsen, J. Petersen
Journal: Allergy (1981)

Basophilocytes from patients with rheumatoid arthritis (RA) responded to leukocyte nuclei from normal persons with histamine release; a similar histamine release induced by the nuclear components RNA and DNA has been demonstrated previously. A role of histamine in RA is also supported by the findings of clinical improvement during treatment with H 1 and H 2 antihistamines in six of 12 patients with RA in active phase, whereas four showed definite deterioration.
Global campaign to eradicate malaria
Authors: G. Yamey
Journal: BMJ (2001)

<h3>Objective.</h3> To determine the level of residual inflammation [synovitis, bone marrow edema (BME), tenosynovitis, and total inflammation] quantified by hand magnetic resonance imaging (h-MRI) in patients with rheumatoid arthritis (RA) in remission according to 3 different definitions of clinical remission, and to compare these remission definitions. <h3>Methods.</h3> A cross-sectional study. To assess the level of residual MRI inflammation in remission, cutoff levels associated to remission and median scores of MRI residual inflammatory lesions were calculated. Data from an MRI register of patients with RA who have various levels of disease activity were used. These were used for the analyses: synovitis, BME according to the Rheumatoid Arthritis Magnetic Resonance Imaging Scoring system, tenosynovitis, total inflammation, and disease activity composite measures recorded at the time of MRI. Receiver-operating characteristic analysis was used to identify the best cutoffs associated with remission for each inflammatory lesion on h-MRI. Median values of each inflammatory lesion for each definition of remission were also calculated. <h3>Results.</h3> A total of 388 h-MRI sets of patients with RA with different levels of disease activity, 130 in remission, were included. Cutoff values associated with remission according to the Simplified Disease Activity Index (SDAI) ≤ 3.3 and the Boolean American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) definitions for BME and tenosynovitis (1 and 3, respectively) were lower than BME and tenosynovitis (2 and 5, respectively) for the Disease Activity Score on 28 joints (DAS28) ≤ 2.6. Median scores for synovitis, BME, and total inflammation were also lower for the SDAI and Boolean ACR/EULAR remission criteria compared with DAS28. <h3>Conclusion.</h3> Patients with RA in remission according to the SDAI and Boolean ACR/EULAR definitions showed lower levels of MRI-detected residual inflammation compared with DAS28.
VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Authors: G Santini, L Salvagno, P Leoni, T Chisesi, C De Souza, M R Sertoli, A Rubagotti, A M Congiu, R Centurioni, A Olivieri, L Tedeschi, M Vespignani, S Nati, M Soracco, A Porcellini, A Contu, C Guarnaccia, N Pescosta, I Majolino, M Spriano, R Vimercati, E Rossi, G Zambaldi, L Mangoni, V Rizzoli
Journal: Journal of Clinical Oncology (1998)

PURPOSE The aim of this multicenter randomized study was to compare conventional therapy with conventional plus high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) as front-line treatment for poor-prognosis non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS Between October 1991 and June 1995, 124 patients, aged 15 to 60 years, with diffuse intermediate- to high-grade NHL (Working Formulation criteria), stages II bulky (&gt; or = 10 cm), III, or IV were enrolled. Sixty-one patients were randomized to receive etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (VACOP-B) for 12 weeks and cisplatin, cytarabine, and dexamethasone (DHAP) as a salvage regimen (arm A), and 63 to receive VACOP-B for 12 weeks plus HDT and ABMT (Arm B). RESULTS There was no significant difference in terms of complete remissions (CRS) in the two groups: 75% in arm A, and 73% in arm B. The median follow-up observation time was 42 months. The 6-year survival probability was 65% in both arms. There was no difference in disease-free survival (DFS) or progression-free survival (PFS) between the two groups. DFS was 60% and 80% (P = .1) and PFS was 48% and 60% (P = .4) for arms A and B, respectively. Procedure feasibility was the major problem. In arm B, 29% of enrolled patients did not undergo HDT and ABMT. A statistical improvement in terms of DFS (P = .008) and a favorable trend in terms of PFS (P = .08) for intermediate-/high- plus high-risk group patients assigned to HDT and ABMT was observed. CONCLUSION In this study, conventional chemotherapy followed by HDT and ABMT as front-line therapy seems no more successful than conventional treatment in terms of overall results. However, our results suggest that controlled studies of HDT plus ABMT should be proposed for higher risk patients.
House dust mite asthma
Authors: H. Mosbech, A. Dirksen, F. Madsen, P. Stahl Skov, B. Weeke
Journal: Allergy (1987)

Fifty asthmatics, candidates for hyposensitization with the house dust mite Dermatophagoides pteronyssinus (Dp), went through a series of allergy tests to evaluate the sensitivity of different organs to Dp. All patients were exposed to bronchial challenge with histamine and bronchial, nasal and conjunctival challenge with Dp, skin prick test (SPT) with Dp, analyses for Dp‐specific histamine release from blood cells (HR) and for anti‐Dp‐IgE in serum (RAST). Results from 40 patients reacting positively in all tests were further analysed. Sensitivity to Dp in the various organs did not parallel, but a fair correlation was demonstrated between pulmonary allergen sensitivity and HR (r = 0.65, P &lt; 0.001), and between pulmonary sensitivity to allergen and to histamine (r = 0.47, P &lt; 0.001). Combined variations in HR and in (unspecific) bronchial sensitivity to histamine explained 53% of the variation in bronchial sensitivity to the allergen. This parameter showed less correlation to RAST and SPT (r = 0.31 and r = 0.35, P &gt; 0.05). The results indicate that bronchial allergen challenge cannot be replaced by similar challenge of other organs, since the sensitivity of the mucosa in different organs of the same patient seems unrelated. Diagnosis should therefore be based on challenge of the organ with dominating clinical importance. In our selected group of patients, however, it was indicated that a substitution of the result of bronchial allergen challenge by measurement of unspecific bronchial reactivity, together with information on the general allergen sensitivity on a cellular level, might be possible. The unpleasant symptoms of the immediate and late bronchial reactions to allergen challenge could thereby be avoided.
Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b
Authors: Aksana Vasilyeva, Selvi Durmus, Lie Li, Els Wagenaar, Shuiying Hu, Alice A. Gibson, John C. Panetta, Sridhar Mani, Alex Sparreboom, Sharyn D. Baker, Alfred H. Schinkel
Journal: Cancer Research (2015)

Recently, an efficient liver detoxification process dubbed "hepatocyte hopping" was proposed on the basis of findings with the endogenous compound, bilirubin glucuronide. According to this model, hepatocytic bilirubin glucuronide can follow a liver-to-blood shuttling loop via Abcc3 transporter-mediated efflux and subsequent Oatp1a/1b-mediated liver uptake. We hypothesized that glucuronide conjugates of xenobiotics, such as the anticancer drug sorafenib, can also undergo hepatocyte hopping. Using transporter-deficient mouse models, we show here that sorafenib-glucuronide can be extruded from hepatocytes into the bile by Abcc2 or back into the systemic circulation by Abcc3, and that it can be taken up efficiently again into neighboring hepatocytes by Oatp1a/1b. We further demonstrate that sorafenib-glucuronide excreted into the gut lumen can be cleaved by microbial enzymes to sorafenib, which is then reabsorbed, supporting its persistence in the systemic circulation. Our results suggest broad relevance of a hepatocyte shuttling process known as "hepatocyte hopping"-a novel concept in clinical pharmacology-for detoxification of targeted cancer drugs that undergo hepatic glucuronidation, such as sorafenib.
Cancer Studies Explore Targeted Therapy, Researchers Seek New Prevention Strategies
Authors: Joan Stephenson
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Studies on Eight Transplantable Plasma-Cell Neoplasms of Mice
Authors: Michael Potter, John L. Fahey
Journal: JNCI Journal of the National Cancer Institute (1960)

Eight plasma-cell neoplasms from mice of strain C3H/He or BALB/cAn, which were associated with the appearance of serum myeloma globulin in each new host, have been maintained in transplant. Each neoplasm was differentiated from the others by a characteristic serum- or urinary-protein electrophoretic pattern that developed during progressive growth of the transplanted tumor. The various plasma-cell neoplasms produced a variety of globulins with electrophoretic mobilities extending from the γ- to the γ-region. Each neoplasm produced proteins that were confined to a part of this globulin region, which indicated a restricted protein-producing capacity. Two neoplasms, which produced similar serum globulin electrophoretic patterns, were differentiated by the appearance of Bence Jones protein in the urine of mice bearing one of the neoplasms but not in mice bearing the other. During serial transplantation, or transplantation to hybrids and certain other strains, the characteristic serum- and urinary-protein changes remained constant and did not change. It was concluded that the globulin production unique to each tumor was a stable heritable characteristic.